Gaurav Shah's most recent trade in Rocket Pharmaceuticals Inc was a trade of 76,490 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 21, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Rocket Pharmaceuticals Inc | Gaurav Shah | CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2026 | 76,490 | 0 | - | - | Stock Option (Right to Buy) | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.69 per share. | 21 May 2026 | 76,490 | 1,117,408 (2%) | 0% | 1.7 | 129,345 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | CEO | Sale of securities on an exchange or to another person at price $ 3.09 per share. | 21 May 2026 | 55,684 | 1,061,724 (1%) | 0% | 3.1 | 171,841 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | CEO | Sale of securities on an exchange or to another person at price $ 3.01 per share. | 19 May 2026 | 2,409 | 1,040,918 (1%) | 0% | 3.0 | 7,261 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | CEO | Sale of securities on an exchange or to another person at price $ 3.61 per share. | 13 May 2026 | 2,728 | 1,043,327 (1%) | 0% | 3.6 | 9,837 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | CEO | Sale of securities on an exchange or to another person at price $ 3.34 per share. | 18 Feb 2026 | 5,990 | 1,046,055 (1%) | 0% | 3.3 | 19,995 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | CEO | Sale of securities on an exchange or to another person at price $ 3.31 per share. | 13 Feb 2026 | 12,279 | 1,052,045 (1%) | 0% | 3.3 | 40,668 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2026 | 870,648 | 870,648 | - | - | Stock Option (Right to Buy) | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2026 | 286,028 | 1,064,324 (1%) | 0% | 0 | Common Stock | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Sale of securities on an exchange or to another person at price $ 2.98 per share. | 18 Nov 2025 | 6,276 | 778,296 (1%) | 0% | 3.0 | 18,721 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.05 per share. | 18 Aug 2025 | 2,234 | 784,572 (1%) | 0% | 3.1 | 6,814 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Sale of securities on an exchange or to another person at price $ 6.45 per share. | 20 May 2025 | 2,253 | 786,806 (1%) | 0% | 6.4 | 14,523 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Sale of securities on an exchange or to another person at price $ 6.53 per share. | 16 May 2025 | 3,621 | 789,059 (1%) | 0% | 6.5 | 23,638 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Purchase of securities on an exchange or from another person at price $ 5.08 per share. | 10 Apr 2025 | 20,000 | 792,680 (1%) | 0% | 5.1 | 101,600 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Sale of securities on an exchange or to another person at price $ 10.58 per share. | 21 Feb 2025 | 16,303 | 772,680 (1%) | 0% | 10.6 | 172,486 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 243,345 | 243,345 | - | - | Stock Option (Right to Buy) | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 81,655 | 788,983 (1%) | 0% | 0 | Common Stock | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Sale of securities on an exchange or to another person at price $ 13.05 per share. | 21 Nov 2024 | 11,091 | 707,328 (1%) | 0% | 13.1 | 144,782 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Sale of securities on an exchange or to another person at price $ 18.50 per share. | 16 Aug 2024 | 9,650 | 718,419 (1%) | 0% | 18.5 | 178,564 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Other type of transaction at price $ 0.00 per share. | 14 May 2024 | 67,785 | 737,859 (1%) | 0% | 0 | Common Stock | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Other type of transaction at price $ 0.00 per share. | 14 May 2024 | 67,785 | 0 | - | - | Restricted Stock Units | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Other type of transaction at price $ 0.00 per share. | 14 May 2024 | 23,940 | 670,074 (1%) | 0% | 0 | Common Stock | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Other type of transaction at price $ 0.00 per share. | 14 May 2024 | 23,940 | 0 | - | - | Restricted Stock Units | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Sale of securities on an exchange or to another person at price $ 23.35 per share. | 14 May 2024 | 9,790 | 728,069 (1%) | 0% | 23.4 | 228,597 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 9,683 | 646,134 (1%) | 0% | 0 | Common Stock | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 9,683 | 67,785 | - | - | Restricted Stock Units | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 7,979 | 636,451 (1%) | 0% | 0 | Common Stock | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 7,979 | 23,940 | - | - | Restricted Stock Units | |
| Rocket Pharmaceuticals Inc | Shah Gaurav | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2024 | 196,336 | 196,336 | - | - | Stock Option (Right to Buy) | |
| Rocket Pharmaceuticals Inc | Shah Gaurav | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2024 | 66,577 | 621,339 (1%) | 0% | 0 | Common Stock | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Sale of securities on an exchange or to another person at price $ 29.84 per share. | 16 Feb 2024 | 20,272 | 554,762 (1%) | 0% | 29.8 | 604,876 | Common Stock |
| Rocket Pharmaceuticals Inc | Shah Gaurav | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 46,828 | 575,034 (1%) | 0% | 0 | Common Stock | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 38,849 | 77,468 | - | - | Restricted Stock Units | |
| Rocket Pharmaceuticals Inc | Shah Gaurav | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 7,979 | 31,919 | - | - | Restricted Stock Units | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Sale of securities on an exchange or to another person at price $ 15.47 per share. | 17 Aug 2023 | 4,767 | 524,854 (0%) | 0% | 15.5 | 73,750 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2023 | 7,979 | 529,621 (0%) | 0% | 0 | Common Stock | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2023 | 7,979 | 47,877 | - | - | Restricted Stock Units | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Sale of securities on an exchange or to another person at price $ 21.38 per share. | 17 May 2023 | 4,122 | 521,642 (0%) | 0% | 21.4 | 88,108 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2023 | 7,979 | 55,856 | - | - | Restricted Stock Units | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2023 | 7,979 | 525,764 (0%) | 0% | 0 | Common Stock | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Sale of securities on an exchange or to another person at price $ 19.06 per share. | 17 Feb 2023 | 12,194 | 536,885 (0%) | 0% | 19.1 | 232,418 | Common Stock |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2023 | 348,590 | 348,590 | - | - | Stock Option (Right to Buy) | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2023 | 116,317 | 116,317 | - | - | Restricted Stock Units | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 31,440 | 549,079 (1%) | 0% | 0 | Common Stock | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 31,440 | 63,835 | - | - | Restricted Stock Units | |
| Talaris Therapeutics Inc | Gaurav Shah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 14,501 | 14,501 | - | - | Stock Option (Right to Buy) | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 297,037 | 297,037 | - | - | Stock Option (Right to Buy) | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 95,275 | 95,275 | - | - | Restricted Stock Units | |
| Rocket Pharmaceuticals Inc | Gaurav Shah | Director, CEO | Purchase of securities on an exchange or from another person at price $ 17.34 per share. | 07 Feb 2022 | 22,000 | 517,639 (0%) | 0% | 17.3 | 381,513 | Common Stock |